PROK PROKIDNEY CORP.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850270 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.2%
TTM net income YoY-45.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-24,830.3%
Net margin-13,326.7%
FCF margin-21,655.0%
EBITDA margin-24,002.1%
Returns
ROE—
ROA-36.8%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets15.8%
Debt / equity—
Current ratio5.04x
Interest coverage-10,690.83x
Cash quality & payout
Operating cash flow / net income1.48x
Accruals ratio17.8%
Payout ratio—
Capex / revenue1,884.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $893,000 | $76,000 |
| R&D expense | $114.12M | $127.67M |
| SG&A expense | $51.78M | $56.08M |
| Operating income | -$165.01M | -$183.68M |
| Interest expense | $4,000 | $9,000 |
| Pretax income | -$151.20M | -$163.93M |
| Income tax | $414,000 | -$598,000 |
| Net income | -$68.99M | -$61.19M |
| EBITDA | -$158.43M | -$178.24M |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $108.54M | $99.12M |
| Current assets | $280.68M | $395.88M |
| PP&E, net | $51.23M | $42.22M |
| Total assets | $335.57M | $441.07M |
| Current liabilities | $30.74M | $36.22M |
| Total liabilities | $34.78M | $39.44M |
| Shareholders' equity | -$1.01B | -$994.95M |
| Cash flow statement | ||
| Operating cash flow | -$120.12M | -$126.35M |
| Capital expenditure | $15.20M | $29.51M |
| Free cash flow | -$135.31M | -$155.86M |
| Investing cash flow | $103.97M | $20.41M |
| Financing cash flow | $25.57M | $144.41M |
| Depreciation & amortization | $6.58M | $5.43M |
| Stock-based compensation | $25.34M | $29.37M |
| Share buybacks | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.